成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 134308-13-7 Chemical Structure| 134308-13-7
Chemical Structure| 134308-13-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 134308-13-7

,{[proInfo.pro_purity]}

Tolcapone is a potent, selective and orally active catechol-O-methyltransferase (COMT) inhibitor with Ki of 30 nM.

Synonyms: Ro 40-7592

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Tolcapone

CAS No. :134308-13-7
Formula : C14H11NO5
M.W : 273.24
SMILES Code : O=C(C1=CC([N+]([O-])=O)=C(O)C(O)=C1)C2=CC=C(C)C=C2
Synonyms :
Ro 40-7592
MDL No. :MFCD00866569
InChI Key :MIQPIUSUKVNLNT-UHFFFAOYSA-N
Pubchem ID :4659569

Safety of Tolcapone

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302+H312-H315-H318-H411
Precautionary Statements:P264-P270-P273-P280-P301+P312+P330-P302+P352+P312-P305+P351+P338+P310-P332+P313-P391-P501
Class:9
UN#:3077
Packing Group:Ⅲ

Isoform Comparison

Biological Activity

Target

  • Transferase

    COMT, Ki:30 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02994719 - Recruiting October 2019 United States, Massachusetts ... More >> Clinical Research Center BIDMC Recruiting Boston, Massachusetts, United States, 02215 Less <<
NCT01158950 Impulsive Behavior Not Applicable Active, not recruiting June 2019 United States, California ... More >> University of California, Berkeley Berkeley, California, United States, 94704 UCSF: Ernest Gallo Clinic and Research Center Emeryville, California, United States, 94591 Less <<
NCT02260570 Mild Traumatic Brain Injury Not Applicable Recruiting June 29, 2019 United States, California ... More >> VA Northern California Health Care System, Mather, CA Recruiting Sacramento, California, United States, 95655 Contact: Andrew S Kayser, MD PhD ?? 925-372-2059 ?? andrew.kayser@va.gov ?? Principal Investigator: Andrew S Kayser, MD PhD Less <<
NCT02949934 Alcohol Use Disorder Phase 2 Recruiting December 2020 United States, South Carolina ... More >> Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29403 Contact: Joseph P Schacht, PhD ?? ?? schacht@musc.edu ?? Principal Investigator: Joseph P Schacht, PhD ?? ?? ?? Principal Investigator: Raymond F Anton, MD Less <<
NCT00906828 Parkinson Disease Phase 4 Completed - Sweden ... More >> Uppsala University Hospital Uppsala, Sweden, 75646 Less <<
NCT01001520 Tobacco Use Disorder Phase 2 Completed - United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT03273062 Brain Injuries ... More >> Brain Injuries, Traumatic Brain Injury, Chronic Less << Phase 2 Recruiting July 20, 2018 United States, Maryland ... More >> Sheppard Pratt Health System Recruiting Towson, Maryland, United States, 21204 Contact: Robert J Schloesser, MD ?? 410-938-4666 ?? rscloesser@sheppardpratt.org Less <<
NCT02448654 Nicotine Dependence Not Applicable Recruiting December 2018 United States, Connecticut ... More >> Veterans Administration Hospital Recruiting West Haven, Connecticut, United States, 06516 Contact: Elise DeVito, Ph.D. ?? 203-737-4882 ?? elise.devito@yale.edu ?? Contact: Stacy Minnix, B.S.W. ?? 203-937-4805 ?? stacy.minnix@yale.edu Less <<
NCT02772978 Pathological Gambling Not Applicable Completed - -
NCT02191826 Familial Amyloid Polyneuropath... More >>y (FAP) Less << Phase 1 Phase 2 Completed - Spain ... More >> Hospital Vall d'Hebron Barcelona, Catalonia, Spain, 08035 Less <<
NCT01001520 - Completed - -
NCT02929485 Addiction Not Applicable Unknown January 2018 United States, California ... More >> University of California, Berkeley Berkeley, California, United States, 94704 University of California, San Francisco San Francisco, California, United States, 94158 Less <<
NCT00044083 Schizophrenia Phase 2 Terminated(Scientific Director... More >> request to use resources for other studies) Less << - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00604591 Frontotemporal Lobar Degenerat... More >>ion Less << Phase 2 Unknown October 2016 United States, New York ... More >> Columbia University Medical Center, 622 West 168th Street New York, New York, United States, 10032 Less <<
NCT02080715 Healthy Phase 1 Completed - Switzerland ... More >> University of Zurich, Institute of Pharmacology and Toxicology Zurich, Switzerland Less <<
NCT00044083 - Terminated(Scientific Director... More >> request to use resources for other studies) Less << - -
NCT00927563 Pathological Gambling PHASE2 COMPLETED 2025-07-12 Ambulatory Research Center, Mi... More >>nneapolis, Minnesota, 55454, United States Less <<
NCT01202955 - Completed - -
NCT02652598 Brain Injuries, Traumatic|Neur... More >>ocognitive Disorders|Brain Injuries Less << PHASE2 UNKNOWN - Sheppard Pratt Health System, ... More >>Baltimore, Maryland, 21204, United States Less <<
NCT00033059 Cocaine-Related Disorders PHASE1 UNKNOWN 2025-03-02 UCLA Integrated Substance Abus... More >>e Program, Los Angeles, California, 90024, United States Less <<
NCT02740582 Alcohol Abuse ... More >> Impulsive Behavior Less << Phase 2 Recruiting December 2019 United States, California ... More >> University of California, Berkeley Recruiting Berkeley, California, United States, 94704 Contact: Jennifer Mitchell, PhD ?? 510-985-3921 ?? Jennifer.Mitchell@ucsf.edu ?? University of California, San Francisco Not yet recruiting San Francisco, California, United States, 94109 Contact: Jennifer Mitchell, PhD ?? 510-985-3921 ?? jennifer.mitchell@ucsf.edu ?? Contact: Allison Coker, PhD ?? 510-985-3522 ?? allison.coker@ucsf.edu Less <<
NCT03348930 Obsessive-Compulsive Disorder Phase 2 Phase 3 Recruiting January 2020 United States, Illinois ... More >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Less <<
NCT01202955 Nicotine Dependence Phase 2 Completed - United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT03591757 Transthyretin Amyloidosis|Amyl... More >>oidosis, Leptomeningeal, Transthyretin-Related Less << EARLY_PHASE1 COMPLETED 2019-04-26 Amyloidosis Center, Boston Med... More >>ical Center, Boston, Massachusetts, 02118, United States Less <<
NCT03633591 Healthy Volunteers Phase 1 Active, not recruiting December 2018 United Kingdom ... More >> Quotient Sciences Ruddington, Nottingham, United Kingdom, NG11 6JS Less <<
NCT02630043 Neuroblastoma Phase 1 Recruiting December 2020 United States, Arkansas ... More >> Arkansas Children's Hospital Recruiting Little Rock, Arkansas, United States, 72202 Contact: Janet Storment, RN ?? 501-364-2760 ?? StormentJanetS@uams.edu ?? Principal Investigator: Kathleen Neville, MD ?? ?? ?? United States, California Rady Children's Hospital Recruiting San Diego, California, United States, 92123 Contact: Mehrzad Milburn ?? 858-966-8155 ?? ?? Principal Investigator: William Roberts, MD ?? ?? ?? United States, Connecticut Connecticut Children's Hospital Not yet recruiting Hartford, Connecticut, United States, 06106 Contact: Sharon Huie-White ?? 860-545-9337 ?? shuie@connecticutchildrens.org ?? Principal Investigator: Michael Isakoff, MD ?? ?? ?? United States, Hawaii Kapiolani Medical Center for Women and Children Recruiting Honolulu, Hawaii, United States, 96813 Contact: Andrea Siu, MPH ?? 808-535-7169 ?? andrea.siu@kapiolani.org ?? Principal Investigator: Randal Wada, MD ?? ?? ?? United States, Michigan Helen DeVos Children's Hospital Recruiting Grand Rapids, Michigan, United States, 49503 Contact: Shannon MacKeigan, R ?? 616-267-1162 ?? shannon.mackeigan@helendevoschildrens.org ?? Principal Investigator: Deanna Mitchell, MD ?? ?? ?? Principal Investigator: Giselle Sholler, MD ?? ?? ?? United States, Missouri Cardinal Glennon Children's Medical Center Recruiting Saint Louis, Missouri, United States, 63104 Contact: Katherine Maxwell, RN ?? 314-268-4000 ?? ?? Principal Investigator: William Ferguson, MD ?? ?? ?? United States, North Carolina Levine Children's Hospital Recruiting Charlotte, North Carolina, United States, 28204 Contact: Nicole Turner, RN ?? 980-442-2355 ?? felisha.turner@carolinashealthcare.org ?? Principal Investigator: Javier Oesterheld, MD ?? ?? ?? United States, Pennsylvania Penn State Milton S. Hershey Medical Center and Children's Hospital Not yet recruiting Hershey, Pennsylvania, United States, 17033 Contact: Suzanne Treadway ?? ?? streadway@hmc.psu.edu ?? Principal Investigator: Valerie Brown, MD ?? ?? ?? United States, South Carolina Medical University of South Carolina Not yet recruiting Charleston, South Carolina, United States, 29425 Contact: Liz Shewfelt ?? 843-792-2957 ?? shewfelt@musc.edu ?? Principal Investigator: Jaqueline Kraveka, MD Less <<
NCT00927563 Pathological Gambling PHASE2 COMPLETED 2025-07-12 Ambulatory Research Center, Mi... More >>nneapolis, Minnesota, 55454, United States Less <<
NCT06387771 Schizophrenia PHASE2 RECRUITING - Clinica Universidad de Navarra... More >>, Pamplona, Navarra, 31008, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.66mL

0.73mL

0.37mL

18.30mL

3.66mL

1.83mL

36.60mL

7.32mL

3.66mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories